2
1
0
My new essay "A Biopharmaceutical Superpower: China’s Rise, Its Limits, and What Comes Next": China’s biopharma revolution is real: once a generics & API giant, it now controls ~80% of global API intermediates, nearly all KSMs for key U.S. drugs, and is closing the gap on
时政
(
twitter.com
)
由
Yanzhong Huang
提交
My new essay "A Biopharmaceutical Superpower: China’s Rise, Its Limits, and What Comes Next": China’s biopharma revolution is real: once a generics & API giant, it now controls ~80% of global API intermediates, nearly all KSMs for key U.S. drugs, and is closing the gap on innovative pipelines. Record licensing deals topped $135B last year—Pfizer alone paid $1.25B for a Chinese bispecific. 1/3 https://t.co/CCcMk19XFw
点击图片查看原图
Markdown支持
评论加载中...
您可能感兴趣的：
1
214
213
213
5
163
162
162
6
496
495
495
10
182
181
181
16
442
441
441
